Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 2/20 | 0.37 |
| ▸ | LAP3 | P28838 | 1/20 | 0.37 |
| ▸ | IL1RN | P18510 | 2/20 | 0.36 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.36 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.35 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14261040 | 1.00 | CA1 (0.52) | CA1CA2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL276673 | 0.87 | SLC1A3 (0.50) | CA1CA2SLC1A3SLC1A2SLC7A5 | |
| SCHEMBL11960690 | 0.83 | CA2 (0.50) | CA1CA2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL14617630 | 0.81 | CA2 (0.48) | CA1CA2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3914198 | 0.81 | CA1 (0.48) | CA1CA2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL18737 | 0.81 | — | — | |
| SCHEMBL27041452 | 0.80 | SLC1A2 (0.64) | CA1CA2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL21014922 | 0.80 | CACNA2D1 (0.45) | CA1CA2SLC1A3SLC1A2SLC7A5 | |
| SCHEMBL12442311 | 0.79 | SLC1A3 (0.47) | CA1CA2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1105036 | 0.79 | SLC1A3 (0.47) | CA1CA2SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351580-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20240067649-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-11827632-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2023-11-28 | — | — | US | disclosed |
| US-20220289736-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-09-15 | — | — | US | disclosed |
| WO-2021195183-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PROTEIN EMBRYONIC ECTODERM DEVELOPMENT ACTIVITY AND TREATING DISEASE | EXO THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| US-9168255-B2 | Quinazoline compounds as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150250789-A1 | QUINAZOLINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-09-10 | — | — | US | disclosed |
| US-9045435-B2 | Quinazoline compounds as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20130289044-A1 | Quinazoline Compounds as Sodium Channel Blockers | PURDUE PHARMA L.P. (US) | 2013-10-31 | — | — | US | disclosed |
| US-7816371-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7498436-B2 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY LLC (US) | 2009-03-03 | — | — | US | disclosed |
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC | 2007-09-13 | — | — | US | disclosed |
| US-20060106256-A1 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY | 2006-05-18 | — | — | US | disclosed |
| EP-0546409-B1 | Method for the preparation of tetrahydropyrancarboxylic esters | BASF AG (DE) | 1998-10-21 | — | — | EP | disclosed |
| EP-0546409-A1 | Method for the preparation of tetrahydropyrancarboxylic esters | BASF Aktiengesellschaft (DE) | 1993-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827632-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | CA1 4083/4885CA2 2938/4885SLC1A3 3498/4885 |
| US-20220289736-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | CA1 4083/4885CA2 2938/4885SLC1A3 3498/4885 |
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, CHAT | CA1 396/4885CA2 1969/4885SLC1A3 69/4885 |
| US-12351580-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | CA1 4083/4885CA2 2938/4885SLC1A3 3498/4885 |
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | CA1 2581/4885CA2 1456/4885SLC1A3 1225/4885 |
| US-20130289044-A1 | Quinazoline Compounds as Sodium Channel Blockers | SCN4A, TRPV1, SCN1B | CA1 2074/4885CA2 397/4885SLC1A3 483/4885 |
| US-20240067649-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | CA1 4083/4885CA2 2938/4885SLC1A3 3498/4885 |
| US-20060106256-A1 | Substituted hydroxyethylamines | HNMT, PNMT, BCHE | CA1 1188/4885CA2 3827/4885SLC1A3 44/4885 |
| US-20150250789-A1 | QUINAZOLINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | SCN4A, TRPV1, SCN1B | CA1 2074/4885CA2 397/4885SLC1A3 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.